$713.96 Million in Sales Expected for Acadia Healthcare Company, Inc. (ACHC) This Quarter
Wall Street brokerages predict that Acadia Healthcare Company, Inc. (NASDAQ:ACHC) will post sales of $713.96 million for the current quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Acadia Healthcare’s earnings, with the highest sales estimate coming in at $723.50 million and the lowest estimate coming in at $708.90 million. Acadia Healthcare posted sales of $702.89 million during the same quarter last year, which would indicate a positive year over year growth rate of 1.6%. The business is scheduled to announce its next quarterly earnings report on Thursday, February 22nd.
According to Zacks, analysts expect that Acadia Healthcare will report full-year sales of $713.96 million for the current year, with estimates ranging from $2.82 billion to $2.84 billion. For the next year, analysts expect that the firm will report sales of $3.01 billion per share, with estimates ranging from $2.99 billion to $3.06 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Acadia Healthcare.
Acadia Healthcare (NASDAQ:ACHC) last released its earnings results on Tuesday, October 24th. The company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.07). Acadia Healthcare had a return on equity of 8.57% and a net margin of 6.07%. The business had revenue of $716.70 million during the quarter, compared to the consensus estimate of $728.86 million. During the same quarter in the previous year, the firm earned $0.58 earnings per share. The firm’s revenue for the quarter was down 2.4% compared to the same quarter last year.
A number of analysts recently commented on the stock. Mizuho boosted their target price on shares of Acadia Healthcare from $57.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Cantor Fitzgerald dropped their target price on shares of Acadia Healthcare from $48.00 to $39.00 and set a “neutral” rating on the stock in a report on Tuesday, October 24th. Craig Hallum reiterated a “buy” rating and issued a $65.00 target price (up from $52.00) on shares of Acadia Healthcare in a report on Monday, July 31st. Deutsche Bank AG boosted their target price on shares of Acadia Healthcare from $58.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, July 31st. Finally, UBS AG reiterated a “positive” rating and issued a $60.00 target price (up from $54.00) on shares of Acadia Healthcare in a report on Monday, July 31st. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $45.15.
Acadia Healthcare (ACHC) traded down $0.40 during midday trading on Friday, hitting $28.23. 1,420,300 shares of the company were exchanged, compared to its average volume of 2,615,914. The company has a debt-to-equity ratio of 1.30, a current ratio of 1.36 and a quick ratio of 1.36. Acadia Healthcare has a twelve month low of $27.88 and a twelve month high of $54.34. The company has a market cap of $2,480.12, a P/E ratio of 12.33, a P/E/G ratio of 1.05 and a beta of 0.89.
In related news, COO Ronald Morgan Fincher sold 80,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $50.69, for a total transaction of $4,055,200.00. Following the transaction, the chief operating officer now directly owns 59,071 shares of the company’s stock, valued at $2,994,308.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joey A. Jacobs sold 500,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $50.69, for a total transaction of $25,345,000.00. Following the transaction, the chief executive officer now directly owns 201,496 shares in the company, valued at $10,213,832.24. The disclosure for this sale can be found here. Insiders have sold 1,824,040 shares of company stock worth $92,460,588 over the last ninety days. 11.10% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Acadia Healthcare by 11.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,704 shares of the company’s stock valued at $134,000 after purchasing an additional 270 shares in the last quarter. C M Bidwell & Associates Ltd. purchased a new position in Acadia Healthcare during the second quarter valued at approximately $205,000. Riverhead Capital Management LLC purchased a new position in Acadia Healthcare during the second quarter valued at approximately $209,000. Rathbone Brothers plc purchased a new position in Acadia Healthcare during the third quarter valued at approximately $223,000. Finally, World Asset Management Inc purchased a new position in Acadia Healthcare during the second quarter valued at approximately $242,000.
Acadia Healthcare Company Profile
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acadia Healthcare Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.